De Novo Pharmaceuticals Ltd., a world leader in computational drug design, has announced that it is expanding its drug design business to establish a new therapeutic focus in the area of metabolic diseases. To help support this and strengthen the Company's scientific base, it has appointed a new Scientific Advisory Board.
Yahoo News (http://biz.yahoo.com/prnews/060509/ukm006.html?.v=57)
